{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:55:10Z","timestamp":1767912910888,"version":"3.49.0"},"reference-count":89,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HOFFMANN-LA ROCHE LTD. (Mississauga, Ontario, Canada)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>(1) Background: Bispecific antibodies (BsAbs) for the treatment of relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL) can be delivered in ambulatory healthcare settings; however, the safe and effective management of potential side effects, such as cytokine release syndrome (CRS), requires protocolized monitoring and management. (2) Methods: An Expert Working Group (EWG) of nine hematologists from across Canada, with experience in leading BsAb program implementation, combined a review of published literature, a comparison of national\/provincial\/regional guidance documents and protocols, and their professional experiences to produce an informed framework for BsAb program implementation in various healthcare settings. (3) Results: The EWG supports and recommends the progression of BsAb provision from predominantly inpatient hospital settings to community\/ambulatory care settings closer to the patient\u2019s home. A seven-step implementation process is outlined to support the safe and effective establishment of such programs, from establishing leadership, through customization of protocols, to education and execution. Strategies and considerations are offered to overcome potential barriers and empower healthcare professionals who are working to establish or improve BsAb programs across Canada. (4) Conclusions: For patients with R\/R DLBCL, the safe and effective provision of BsAbs closer to home is both feasible and preferred. This guidance is intended to support the efficient and effective setup or enhancement of BsAb programs in lymphoma.<\/jats:p>","DOI":"10.3390\/curroncol32080460","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T14:24:28Z","timestamp":1755267868000},"page":"460","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Practical Guidance for the Expanded Implementation and Provision of Bispecific Antibodies for Diffuse Large B-Cell Lymphoma (DLBCL) Across Canada"],"prefix":"10.3390","volume":"32","author":[{"given":"David","family":"MacDonald","sequence":"first","affiliation":[{"name":"Division of Hematology, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Puckrin","sequence":"additional","affiliation":[{"name":"Arthur J.E. Child Comprehensive Cancer Centre, Calgary, AB T2N 5G2, Canada"},{"name":"Department of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Skrabek","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology\/Hematology, Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3A TR9, Canada"},{"name":"CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selay","family":"Lam","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Western University, London Health Sciences Centre, London, ON N6A 5W9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jai","family":"Jayakar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Southlake Health, Newmarket, ON L3Y 2P9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Fleury","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Cell Therapy University Institute, H\u00f4pital Maisonneuve-Rosemont, Montr\u00e9al, QC H1T 2M4, Canada"},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H3T 1J4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0281-5866","authenticated-orcid":false,"given":"Christopher","family":"Lemieux","sequence":"additional","affiliation":[{"name":"Divison of Hemato-Oncology and Transplantation, CHU de Qu\u00e9bec-Universit\u00e9, Laval, QC G1V 0E8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lina","family":"Boutin","sequence":"additional","affiliation":[{"name":"Division of Hemato-Oncology, Charles-Lemoyne Research Center, Greenfield Park, QC J4V 2G9, Canada"},{"name":"Facult\u00e9 de M\u00e9decine et des Sciences de la Sant\u00e9, Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Costello","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Memorial University of Newfoundland, St. John\u2019s, NL A1B 3V6, Canada"},{"name":"Eastern Health, St. John\u2019s, NL A1B 3V6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e7448","DOI":"10.1002\/cam4.7448","article-title":"Real Life Clinical Outcomes of Relapsed\/Refractory Diffuse Large B Cell Lymphoma in the Rituximab Era: The STRIDER Study","volume":"13","author":"Dogliotti","year":"2024","journal-title":"Cancer Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.clml.2024.05.010","article-title":"SOHO State of the Art Updates and Next Questions|Current Evidence and Future Directions for Bispecific Antibodies in Large B-Cell Lymphoma","volume":"24","author":"Bennett","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse Large B-Cell Lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","unstructured":"Shaefy, M., Savage, K.J., Skrabek, P., Keating, M.-M., Tsang, R., Bosch, M., and Kuruvilla, J. (2021). Canadian Evidence-Based Guideline for the Frontline Treatment of Diffuse Large B-Cell Lymphoma, Lymphoma Canada."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e3202","DOI":"10.1002\/hon.3202","article-title":"Diffuse Large B-Cell Lymphoma","volume":"42","author":"Barraclough","year":"2024","journal-title":"Hematol. Oncol."},{"key":"ref_7","unstructured":"Shaefy, M., Savage, K.J., Skrabek, P., Elsawy, M., Tsang, R., Bosch, M., and Kuruvilla, J. (2021). Canadian Evidence-Based Guideline for the Treatment of Relapsed\/Refractory Diffuse Large B-Cell Lymphoma, Lymphoma Canada."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1053\/j.seminhematol.2023.12.001","article-title":"Second-Line Treatment of Diffuse Large B-Cell Lymphoma: Evolution of Options","volume":"60","author":"Fabbri","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma: Primary Analysis of the Phase 3 TRANSFORM Study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"ref_11","unstructured":"Abbvie Corporation (2023). EPKINLY (Epcoritamab) Product Monograph, Health Canada."},{"key":"ref_12","unstructured":"Hoffmann-La Roche Limited (2023). COLUMVI (Glofitamab) Product Monograph, Health Canada."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/hon.3163_95","article-title":"Glofitamab Monotherapy in Patients with Relapsed\/Refractory (r\/R) Large B-Cell Lymphoma (Lbcl): Extended Follow-up and Landmark Analyses from a Pivotal Phase Ii Study","volume":"41","author":"Dickinson","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in Relapsed\/Refractory Large B-Cell Lymphoma: 2-Year Follow-up from the Pivotal EPCORE NHL-1 Trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","article-title":"Odronextamab Monotherapy in Patients with Relapsed\/Refractory Diffuse Large B Cell Lymphoma: Primary Efficacy and Safety Analysis in Phase 2 ELM-2 Trial","volume":"6","author":"Kim","year":"2025","journal-title":"Nat. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.clml.2024.11.005","article-title":"SOHO State of the Art Updates and Next Questions|Diffuse Large B-Cell Lymphoma in Older Adults: A Comprehensive Review","volume":"25","author":"Iyengar","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus Gemcitabine and Oxaliplatin (GemOx) versus Rituximab-GemOx for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (STARGLO): A Global Phase 3, Randomised, Open-Label Trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood-2024-199330","article-title":"Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study","volume":"144","author":"Brooks","year":"2024","journal-title":"Blood"},{"key":"ref_21","unstructured":"CCO (2024). Drug Formulary\u2014Epcoritamab, Cancer Care Ontario."},{"key":"ref_22","unstructured":"CCO (2024). Drug Formulary\u2014Glofitamab, Cancer Care Ontario."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.3324\/haematol.2024.285255","article-title":"Sequencing of Cellular Therapy and Bispecific Antibodies for the Management of Diffuse Large B-Cell Lymphoma","volume":"109","author":"Melody","year":"2024","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/blood.2024024788","article-title":"How I Treat Older Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"145","author":"Wallace","year":"2024","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","article-title":"Bispecific Antibodies and CAR-T Cells: Dueling Immunotherapies for Large B-Cell Lymphomas","volume":"14","author":"Trabolsi","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/17474086.2023.2285978","article-title":"Dual Target Dilemma: Navigating Epcoritamab vs. Glofitamab in Relapsed Refractory Diffuse Large B-Cell Lymphoma","volume":"16","author":"Davis","year":"2023","journal-title":"Expert. Rev. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2147\/PPA.S485838","article-title":"Novel Bispecific T-Cell Engagers for the Treatment of Relapsed B Cell Non-Hodgkin Lymphomas: Current Knowledge and Treatment Considerations","volume":"18","author":"Varon","year":"2024","journal-title":"Patient Prefer. Adherence"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Fleury, I., MacDonald, D., Shafey, M., Christofides, A., and Sehn, L.H. (2025). Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada. Curr. Oncol., 32.","DOI":"10.20944\/preprints202501.1882.v2"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yang, C., Nguyen, J., and Yen, Y. (2023). Complete Spectrum of Adverse Events Associated with Chimeric Antigen Receptor (CAR)-T Cell Therapies. J. Biomed. Sci., 30.","DOI":"10.1186\/s12929-023-00982-8"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood.2023023419","article-title":"CAR T Cells vs Bispecific Antibody as Third- or Later-Line Large B-Cell Lymphoma Therapy: A Meta-Analysis","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Falchi, L., Hutchings, M., Carlo-Stella, C., Morschhauser, F., Dickinson, M., Cartron, G., Khan, C., Tani, M., Martinez-Lopez, J., and Bartlett, N.L. (2024). Dexamethasone Is Associated with Reduced Frequency and Intensity of Cytokine Release Syndrome Compared with Alternative Corticosteroid Regimens as Premedication for Glofitamab in Patients with Relapsed\/Refractory Large B-Cell Lymphoma. Haematologica.","DOI":"10.3324\/haematol.2024.286257"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2023-180333","article-title":"Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1","volume":"142","author":"Vose","year":"2023","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus Recommendations on the Management of Toxicity Associated with CD3\u00d7CD20 Bispecific Antibody Therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Lancman, G., Song, K., White, D., Crosbie, T., Sharif, I., Emond, M., Saleem Raza, M., Elias, M., Kaedbey, R., and Chu, M.P. (2024). Recommendations for the Effective Use of T-Cell-Redirecting Therapies: A Canadian Consensus Statement. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1446995"},{"key":"ref_36","unstructured":"INESSS (2025). Bispecific Therapies and Tumour-Infiltrating T Cell Therapies: Considerations for Deployment in Quebec, Institut National D\u2019excellence en Sant\u00e9 et en Services Sociaux (INESSS)."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/SPC.0000000000000699","article-title":"Supportive Care Measures for Bispecific T-Cell Engager Therapies in Haematological Malignancies","volume":"18","author":"Chen","year":"2024","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and Management of Adverse Events during Treatment with Bispecific Antibodies and CAR T Cells in Multiple Myeloma: A Consensus Report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_39","first-page":"2430","article-title":"How I Treat Refractory CRS and ICANS after CAR T-Cell Therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"CADTH (2024). Epcoritamab (Epkinly): CADTH Reimbursement Recommendation, Canadian Agency for Drugs and Technologies in Health.","DOI":"10.51731\/cjht.2024.923"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"CADTH (2024). Glofitamab (Columvi): CADTH Reimbursement Recommendation, Canadian Agency for Drugs and Technologies in Health.","DOI":"10.51731\/cjht.2024.873"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6923","DOI":"10.1182\/blood-2023-179044","article-title":"CAR-T Therapy for the Treatment of Relapsed\/Refractory CD19 Positive Large B Cell Lymphoma: Canadian Real-World Evidence","volume":"142","author":"Tan","year":"2023","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e433516","DOI":"10.1200\/EDBK_433516","article-title":"Bispecific Antibody Use in Patients with Lymphoma and Multiple Myeloma","volume":"44","author":"Braun","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Esteghamat, N., Tsumura, A., Marquez-Arreguin, G., and Tuscano, J. (2024). Cellular Therapy in Older Adults with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1481950"},{"key":"ref_45","unstructured":"CCO (2025). Guidelines and Advice: T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS), Cancer Care Ontario."},{"key":"ref_46","unstructured":"Statistics Canada (2022). Canadian Census 2021: Population Growth in Canada\u2019s Rural Areas, 2016 to 2021, Statistics Canada."},{"key":"ref_47","unstructured":"CCO (2024). Organizational Readiness Recommendations for Delivering T-Cell Engaging Antibodies, Cancer Care Ontario."},{"key":"ref_48","unstructured":"ACCC (2022). ACCC Bispecifics Implementation, Association of Community Cancer Centers."},{"key":"ref_49","unstructured":"Saskatchewan Cancer Agency (2018). Referral Form, Saskatchewan Cancer Agency."},{"key":"ref_50","unstructured":"AHS (2020). EMR Referral Form, Alberta Health Services."},{"key":"ref_51","unstructured":"Hamilton Health Sciences (2020). Hamilton Health Sciences Autologous Stem Cell Transplant Referral Form, Hamilton Health Sciences."},{"key":"ref_52","unstructured":"BCCA (2005). Cancer Management Manual > Required Reports for Referrals > Lymphoma & Leukemia, BCCA."},{"key":"ref_53","unstructured":"AHS (2025). Alberta Referral Directory > Malignant Hematology, Alberta Health Services."},{"key":"ref_54","unstructured":"BCCA (2024). Bispecific Antibody Nursing Process, BC Cancer Agency."},{"key":"ref_55","unstructured":"Canadian Cancer Society (2025). How We Can Help > Transportation, Canadian Cancer Society."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"van der Linde, S., Knights, E., Robertson, M., Krishnasamy, M., Minson, A., and Dickinson, M. (2024). Preparing Nurses for CD20-CD3 Bispecific Antibody Treatment in Patients with Non-Hodgkin Lymphoma: A Scoping Review of Adverse Events and Management Strategies From Early Phase and Pivotal Trials. Cancer Nurs.","DOI":"10.1097\/NCC.0000000000001419"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/bloodadvances.2023011089","article-title":"Predictive Model for the Risk of Cytokine Release Syndrome with Glofitamab Treatment for Diffuse Large B-Cell Lymphoma","volume":"8","author":"Gritti","year":"2024","journal-title":"Blood Adv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1182\/blood-2024-200957","article-title":"Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy","volume":"144","author":"Thieblemont","year":"2024","journal-title":"Blood"},{"key":"ref_59","unstructured":"Cancer Care Alberta (2024). Information for Patients and Families\u2014Bispecific Antibodies, Alberta Health Services."},{"key":"ref_60","unstructured":"CCO (2024). T-Cell-Engaging Antibodies\u2014What You Need to Know, Cancer Care Ontario."},{"key":"ref_61","unstructured":"BCCA (2024). For the Patient: Epcoritamab Handout, BC Cancer Agency."},{"key":"ref_62","unstructured":"LLSC (2023). Managing Side Effects > Cytokine Release Syndrome, Leukemia & Lymphoma Society of Canada."},{"key":"ref_63","unstructured":"LLSC (2024). Managing Side Effects > Immune Effector Cell-Associated Neurotoxicity Syndrome ICANS, Leukemia & Lymphoma Society of Canada."},{"key":"ref_64","unstructured":"BCCA (2024). For the Patient: Management of CRS and ICANS, BC Cancer Agency."},{"key":"ref_65","unstructured":"Cancer Care Alberta (2024). Bispecific Antibodies Emergency Contact Card, Alberta Health Services."},{"key":"ref_66","unstructured":"BCCA (2024). Bispecific Antibody Alert Card, BC Cancer Agency."},{"key":"ref_67","unstructured":"CCO (2025). T-Cell-Engaging Antibody Treatment: Wallet Card, Cancer Care Ontario."},{"key":"ref_68","unstructured":"Cancer Care Alberta (2024). Bispecific Antibodies Triage Letter, Alberta Health Services."},{"key":"ref_69","unstructured":"BCCA (2024). Bispecific Antibody Patient Letter, BC Cancer Agency."},{"key":"ref_70","unstructured":"CCMB (2024). Regimen Reference Order\u2014LYMP\u2014Epcoritamab, Cancer Care Manitoba."},{"key":"ref_71","unstructured":"CCMB (2024). Regimen Reference Order\u2014LYMP\u2014Glofitamab, Cancer Care Manitoba."},{"key":"ref_72","unstructured":"Hoffmann-La Roche Limited (2022). GAZYVA (Obinutuzumab) Product Monograph, Health Canada."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1182\/blood-2024-203426","article-title":"Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab","volume":"144","author":"Kowalski","year":"2024","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1002\/hem3.132","article-title":"Prophylactic Tocilizumab Reduces the Incidence of Cytokine Release Syndrome in Relapsed\/Refractory Myeloma Patients Treated with Teclistamab: Implications for Outpatient Step-up Dosing","volume":"8","author":"Korst","year":"2024","journal-title":"Hemasphere"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41408-023-00963-y","article-title":"Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab: A Single-Center Experience","volume":"13","author":"Scott","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"7517","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Longer-Term Follow-up of Patients (Pts) Receiving Prophylactic Tocilizumab (Toci) for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1\/2 MajesTEC-1 Study of Teclistamab in Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"42","author":"Garfall","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2022-159381","article-title":"Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity","volume":"140","author":"Trudel","year":"2022","journal-title":"Blood"},{"key":"ref_78","unstructured":"BCCA (2025). Protocol Summary for Treatment of Lymphoma Using Epcoritamab, BC Cancer Agency."},{"key":"ref_79","unstructured":"INESSS (2024). Extract Notice to the Minister Epkinly (LGCB), INESSS."},{"key":"ref_80","unstructured":"INESSS (2024). Extract Notice to the Minister Columvi (LDGCB), INESSS."},{"key":"ref_81","unstructured":"Cancer Care Alberta (2024). Clinical Practice Guideline, Lymphoma > Prevention and Management of Toxicities of Bispecific Antibodies in Lymphoma, Alberta Health Services."},{"key":"ref_82","unstructured":"BCCA (2025). BC Cancer Protocol for Cytokine Release Syndrome Management, BC Cancer Agency."},{"key":"ref_83","unstructured":"BCCA (2024). BC Cancer Protocol for Immune Effector Cell-Associated Neurotoxicity Syndrome Management, BC Cancer Agency."},{"key":"ref_84","unstructured":"BCCA (2025). Supportive Care CRS Doctor\u2019s Orders, BC Cancer Agency."},{"key":"ref_85","unstructured":"BCCA (2024). Supportive Care ICANS Doctor\u2019s Orders, BC Cancer Agency."},{"key":"ref_86","unstructured":"CMA (2025). Why Are ER Times So Long in Canada?, Canadian Medical Association."},{"key":"ref_87","unstructured":"CDA-AMC (2024). Virtual Medicine Wards and Hospital-At-Home Programs, Canada\u2019s Drug Agency-L\u2019Agence des medicaments du Canada."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2024-198714","article-title":"3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma","volume":"144","author":"Karimi","year":"2024","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2024-194333","article-title":"Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study","volume":"144","author":"Dickinson","year":"2024","journal-title":"Blood"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/8\/460\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:28:21Z","timestamp":1760034501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/8\/460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":89,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["curroncol32080460"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32080460","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]}}}